4.0 Article

Automated CT Staging of Chronic Obstructive Pulmonary Disease Severity for Predicting Disease Progression and Mortality with a Deep Learning Convolutional Neural Network

Journal

RADIOLOGY-CARDIOTHORACIC IMAGING
Volume 3, Issue 2, Pages -

Publisher

RADIOLOGICAL SOC NORTH AMERICA (RSNA)
DOI: 10.1148/ryct.2021200477

Keywords

-

Funding

  1. U.S. National Library of Medicine [T15LM011271]
  2. National Institutes of Health [T32 EB005970]
  3. Radiological Society of North America [RR1879]
  4. National Heart, Lung, and Blood Institute [U01 HL089897, U01 HL089856]
  5. COPD Foundation
  6. AstraZeneca
  7. Bayer Pharmaceuticals
  8. Boehringer-Ingelheim
  9. Genentech
  10. GlaxoSmithKline
  11. Novartis
  12. Pfizer
  13. Sunovion

Ask authors/readers for more resources

A deep learning-based algorithm was developed to stage the severity of COPD by quantifying emphysema and air trapping on CT images, with promising ability to predict 5-year progression and mortality. The study found significant associations between CT stages and disease progression and mortality.
Purpose: To develop a deep learning-based algorithm to stage the severity of chronic obstructive pulmonary disease (COPD) through quantification of emphysema and air trapping on CT images and to assess the ability of the proposed stages to prognosticate 5-year progression and mortality. Materials and Methods: In this retrospective study, an algorithm using co-registration and lung segmentation was developed in-house to automate quantification of emphysema and air trapping from inspiratory and expiratory CT images. The algorithm was then tested in a separate group of 8951 patients from the COPD Genetic Epidemiology study (date range, 2007-2017). With measurements of emphysema and air trapping, bivariable thresholds were determined to define CT stages of severity (mild, moderate, severe, and very severe) and were evaluated for their ability to prognosticate disease progression and mortality using logistic regression and Cox regression. Results: On the basis of CT stages, the odds of disease progression were greatest among patients with very severe disease (odds ratio [OR], 2.67; 95% CI: 2.02, 3.53; P,.001) and were elevated in patients with moderate disease (OR, 1.50; 95% CI: 1.22, 1.84; P =.001). The hazard ratio of mortality for very severe disease at CT was 2.23 times the normal ratio (95% CI: 1.93, 2.58; P,.001). When combined with Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging, patients with GOLD stage 2 disease had the greatest odds of disease progression when the CT stage was severe (OR, 4.48; 95% CI: 3.18, 6.31; P,.001) or very severe (OR, 4.72; 95% CI: 3.13, 7.13; P,.001). Conclusion: Automated CT algorithms can facilitate staging of COPD severity, have diagnostic performance comparable with that of spirometric GOLD staging, and provide further prognostic value when used in conjunction with GOLD staging.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available